about
Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral DrugsGold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN.Mucosal microbiome in patients with recurrent aphthous stomatitisDrug transporter gene expression in human colorectal tissue and cell lines: modulation with antiretrovirals for microbicide optimization.Transporters for Antiretroviral Drugs in Colorectal CD4+ T Cells and Circulating α4β7 Integrin CD4+ T Cells: Implications for HIV Microbicides.Susceptibility to chlorhexidine amongst multidrug-resistant clinical isolates of Staphylococcus epidermidis from bloodstream infections.Predictive value of the admissions process and the UK Clinical Aptitude Test in a graduate-entry dental school.Draft Whole-Genome Sequences of Periodontal Pathobionts Porphyromonas gingivalis, Prevotella intermedia, and Tannerella forsythia Contain Phase-Variable Restriction-Modification Systems.Panton-Valentine leukocidin-positive Staphylococcus aureus: a position statement from the International Society of Chemotherapy.Corrigendum to 'Panton-Valentine Leucocidin (PVL) Staphylococcus aureus a position statement from the International Society of Chemotherapy' [International Journal of Antimicrobial Agents 51/1 (2018) 16-25].Hot topics in necrotising skin and soft tissue infections.Time for biocide stewardship?In Vivo Modulation of Cervicovaginal Drug Transporters and Tissue Distribution by Film-Released Tenofovir and Darunavir for Topical Prevention of HIV-1An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC)Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients
P50
Q28548592-82E1012A-0F15-45F5-8AB5-67C6A2BE5CA0Q33493474-9A297619-500F-4DD0-BE99-D96E94938EA2Q35533970-577B4ECA-352B-4A99-AE93-C6E18FE38B7BQ38823939-9E858CC5-EE73-4F49-AAED-5422F3BAB506Q40596923-7123C8AD-5531-4025-9A7A-DC97B3AEA600Q40657479-3DA80A47-5978-4343-AD2E-D33A147BE926Q40793938-086D2462-5847-49F9-BDB5-52091324ED07Q46888693-DB04D13C-FFB2-47F3-8755-FC60F3F4A4EAQ48549522-1B7962C6-83CA-41A6-8E73-AD005E755EF5Q52806854-2B914C7A-0D63-48E8-8A7B-ADA5B17FAB92Q54262730-5FEFD5CE-EEC0-4D58-8DB0-86F843CC0095Q62671373-DFEC5464-FF02-40CB-A92E-459876B8DEC7Q89526491-01AF6BA1-2A68-47A7-956D-4FB31271E397Q91627320-CF4C2720-F945-4704-9A17-FAA8567FECE2Q92112012-C3FB7184-2830-47FC-AA7A-7A816E68FDD2
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Karolin Hijazi
@en
Karolin Hijazi
@nl
type
label
Karolin Hijazi
@en
Karolin Hijazi
@nl
prefLabel
Karolin Hijazi
@en
Karolin Hijazi
@nl
P31
P496
0000-0002-8589-2129